RedHill Biopharma (RDHL) Non-Current Assets (2012 - 2025)

RedHill Biopharma (RDHL) has 14 years of Non-Current Assets data on file, last reported at $18.8 million in Q4 2025.

• On a quarterly basis, Non-Current Assets rose 206.87% year-over-year to $18.8 million in Q4 2025; TTM through Dec 2025 was $37.2 million, a 506.64% increase from a year earlier, with the FY2025 full-year figure at $18.8 million, up 206.87% from the prior year.
• Non-Current Assets for Q4 2025 stood at $18.8 million, up from $5.8 million in the prior quarter.
• Over the last five years, Non-Current Assets for RDHL reached as high as $105.2 million in Q2 2021 and fell as low as $5.8 million in Q2 2025.
• Historically, Non-Current Assets has averaged $39.9 million across 5 years, with a median of $13.4 million in 2023.
• Across the five-year window, Non-Current Assets slumped 90.53% in 2023 and jumped 206.87% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $92.0 million in 2021, then decreased by 20.72% to $73.0 million in 2022, then slumped by 90.53% to $6.9 million in 2023, then retreated by 11.22% to $6.1 million in 2024, then soared by 206.87% to $18.8 million in 2025.
• Per Business Quant data, the three most recent Non-Current Assets figures were $18.8 million in Q4 2025, $5.8 million in Q2 2025, and $6.1 million in Q4 2024.